Pfizer (NYSE: PFE) has faced significant challenges, with its shares declining over 60% from their peak due to a multi-year downturn following high pandemic-related sales. Despite this decline, the company’s strong history and a 7.3% dividend yield suggest potential value, prompting a closer examination of its current situation. The article explores the reasons behind Pfizer’s struggles and assesses whether it might be a good opportunity to buy the dip in its stock price.
